Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents
Publication Date: June 4, 2019
Key Points
Key Points
Use of erythropoiesis-stimulating agents (ESAs) to manage anemia raises hemoglobin levels and reduces the need for red blood cell transfusions but increases the risk of thromboembolic events.
ESAs are indicated in cancer patients who are receiving myelosuppressive chemotherapy with non-curative intent and anemia that cannot be adequately managed with transfusional support.
ESAs are indicated in cancer patients who are receiving myelosuppressive chemotherapy with non-curative intent and anemia that cannot be adequately managed with transfusional support.
Treatment
...T...
...clinical circumstances ESAs may be...
...be offered to patients with chemotherapy-assoc...
...s should not be offered to most patients wit...
...ered to patients with lower risk myelodysplas...
In patients with myeloma, non-Hodgkin’s...
...ering an ESA, clinicians should conduct...
...Panel considers epoetin beta and al...
...the risk of thromboembolism, and clinicians sho...
...recommended that starting and modifying doses...
Hb may be increased to the lowest concen...
ESAs should be discontinued in patients who...
...t may be used to improve hemoglobin r...
...1. Suggested Baseline Investigations for An...
...Adult Dosing Dose and Modifications...
...able 3. Estimated Prices of ESAs and Supp...